NASDAQ:DEPO - Depomed Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $7.30 +0.12 (+1.67 %) (As of 10/17/2018 03:58 AM ET)Previous Close$7.18Today's Range$7.09 - $7.4252-Week Range$4.31 - $9.48Volume940,193 shsAverage Volume1.30 million shsMarket Capitalization$461.47 millionP/E Ratio-5.79Dividend YieldN/ABeta1.27 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Depomed, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults. The company also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, it is involved in the clinical development of Cebranopadol for the treatment of chronic nociceptive and neuropathic pain. Depomed, Inc. has a collaboration and license agreement with Ironwood Pharmaceuticals, Inc.; and a license agreement with Janssen Pharmaceuticals, Inc. based on its proprietary Acuform gastroretentive drug delivery technology. The company sells its products to wholesalers and retail pharmacies. Depomed, Inc. was founded in 1995 and is headquartered in Newark, California. Receive DEPO News and Ratings via Email Sign-up to receive the latest news and ratings for DEPO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical SymbolNASDAQ:DEPO CUSIP24990810 Webwww.depomedinc.com Phone510-744-8000 Debt Debt-to-Equity Ratio2.48 Current Ratio0.55 Quick Ratio0.53 Price-To-Earnings Trailing P/E Ratio-5.79 Forward P/E Ratio-15.21 P/E GrowthN/A Sales & Book Value Annual Sales$380.72 million Price / Sales1.23 Cash Flow$0.8459 per share Price / Cash8.63 Book Value$2.69 per share Price / Book2.71 Profitability EPS (Most Recent Fiscal Year)($1.26) Net Income$-102,490,000.00 Net Margins-9.52% Return on Equity-13.22% Return on Assets-2.52% Miscellaneous Employees434 Outstanding Shares63,920,000Market Cap$461.47 million Depomed (NASDAQ:DEPO) Frequently Asked Questions What is Depomed's stock symbol? Depomed trades on the NASDAQ under the ticker symbol "DEPO." How were Depomed's earnings last quarter? Depomed Inc (NASDAQ:DEPO) released its quarterly earnings data on Wednesday, August, 8th. The specialty pharmaceutical company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.16 by $0.03. The specialty pharmaceutical company had revenue of $63.27 million for the quarter, compared to analyst estimates of $63.72 million. Depomed had a negative net margin of 9.52% and a negative return on equity of 13.22%. Depomed's quarterly revenue was down 37.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.08 earnings per share. View Depomed's Earnings History. When is Depomed's next earnings date? Depomed is scheduled to release their next quarterly earnings announcement on Tuesday, November 6th 2018. View Earnings Estimates for Depomed. What price target have analysts set for DEPO? 7 Wall Street analysts have issued twelve-month target prices for Depomed's shares. Their forecasts range from $7.00 to $10.00. On average, they anticipate Depomed's stock price to reach $8.6667 in the next year. This suggests a possible upside of 18.7% from the stock's current price. View Analyst Price Targets for Depomed. What is the consensus analysts' recommendation for Depomed? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Depomed in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Depomed. Who are some of Depomed's key competitors? Some companies that are related to Depomed include Myovant Sciences (MYOV), Theravance Biopharma (TBPH), Nabriva Therapeutics (NBRV), Spectrum Pharmaceuticals (SPPI), Zogenix (ZGNX), Portola Pharmaceuticals (PTLA), G1 Therapeutics (GTHX), Puma Biotechnology (PBYI), Phibro Animal Health (PAHC), Arrowhead Pharmaceuticals (ARWR), Enanta Pharmaceuticals (ENTA), Akorn (AKRX), Corcept Therapeutics (CORT), Aimmune Therapeutics (AIMT) and Insmed (INSM). Who are Depomed's key executives? Depomed's management team includes the folowing people: Mr. Arthur Joseph Higgins, CEO, Pres & Director (Age 62)Mr. August J. Moretti, CFO & Sr. VP (Age 67)Mr. Sean P. McKercher, Sr. VP of Operations & Bus. (Age 61)Dr. Stan Bukofzer, Sr. VP and Chief Medical & Scientific Officer (Age 62)Mr. John B. Thomas, Sr. VP of IR & Corp. Communications (Age 54) How do I buy shares of Depomed? Shares of DEPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Depomed's stock price today? One share of DEPO stock can currently be purchased for approximately $7.30. How big of a company is Depomed? Depomed has a market capitalization of $461.47 million and generates $380.72 million in revenue each year. The specialty pharmaceutical company earns $-102,490,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Depomed employs 434 workers across the globe. What is Depomed's official website? The official website for Depomed is http://www.depomedinc.com. How can I contact Depomed? Depomed's mailing address is 7999 GATEWAY BLVD. SUITE 300, NEWARK CA, 94560. The specialty pharmaceutical company can be reached via phone at 510-744-8000 or via email at [email protected] MarketBeat Community Rating for Depomed (NASDAQ DEPO)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 447 (Vote Outperform)Underperform Votes: 346 (Vote Underperform)Total Votes: 793MarketBeat's community ratings are surveys of what our community members think about Depomed and other stocks. Vote "Outperform" if you believe DEPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DEPO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/17/2018 by MarketBeat.com StaffFeatured Article: Should You Consider an Index Fund?